HBV+DEN-treated TregST2CKO mice showed significantly lower liver tumor burden, improved liver architecture, and decreased PCNA+ proliferating hepatocytes compared with HBV+DEN-treated WT mice at 8 months post-infection (Fig. 4a–e and Supplementary Fig. 6a). Here, PCNA is linked to infection.